Customize your JAMA Network experience by selecting one or more topics from the list below.
Simpson AN, Simpson KN, Dubno JR. Higher Health Care Costs in Middle-aged US Adults With Hearing Loss. JAMA Otolaryngol Head Neck Surg. 2016;142(6):607–609. doi:10.1001/jamaoto.2016.0188
Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Age-related hearing loss affects more than 60% of US adults older than 70 years and has been associated with increased risk of hospitalization,1 decreased quality of life,2,3 and increased risk of functional and cognitive decline.4 The onset of hearing loss is gradual, with prevalence tripling from the age of 50 years to 60 years.3 However, the association between hearing loss in older middle-aged adults (aged 55-64 years) and the use of health care has not been studied. We compared the costs of health care for a matched cohort of privately insured individuals with and without a diagnosis of hearing loss.
Using the Truven Health MarketScan database from January 1, 2009, to December 31, 2013, of privately insured individuals with at least 18 months of coverage, we extracted data on a cohort of patients aged 55 to 64 years with an International Classification of Diseases, Ninth Revision, code for hearing loss (codes V41.2, V72.1x, 388.00, 388.01, 388.40, 388.43, 388.44, 388.5, 389.1x, and 389.2x). We then propensity score matched them with a comparison group based on age, sex, US region, insurance type, beneficiary status, Charlson comorbidity score,5 use of outpatient services, and baseline presence of 22 chronic conditions (asthma, carditis, chronic obstructive pulmonary disease, chronic renal failure, conductive heart disease, congestive heart failure, cystic fibrosis, diabetes mellitus type 2, diverticulitis, epilepsy, heart valve disease, hepatitis, human immunodeficiency virus, hypertension, multiple sclerosis, Parkinson disease, pulmonary heart disease, rheumatoid arthritis, schizophrenia, systemic lupus, senile dementia, and sickle cell disease). Owing to very small cell sizes, cystic fibrosis, diverticulitis, heart valve disease, human immunodeficiency virus, multiple sclerosis, and schizophrenia were not used in the final matching model. Six months of baseline data for each individual were used for matching. Patients with diagnoses of late effects of stroke, coma, or paralysis were excluded. Health care bills for up to 18 months of follow-up after baseline were summed by patient to calculate total payments for inpatient services, outpatient services, prescription medication, and cost of hearing services. Payments were compared by group using gamma distributed, generalized, linear log-transformed models, adjusting for baseline covariates (demographic characteristics, chronic conditions, Charlson comorbidity score, number of days in the follow-up period, and use of hearing services). Data analysis was conducted using SAS, version 9.4 (SAS Institute Inc), with α < .05. The study protocol was approved by the Medical University of South Carolina Institutional Review Board. Patient consent was not required because data were deidentified and the Medical University of South Carolina Institutional Review Board classified this study as nonhuman research.
A total of 561 764 individuals were included in the study. Groups were balanced (standardized mean differences on all covariates, <20%).6 Descriptive characteristics of the matched groups at baseline are shown in Table 1. Fully adjusted models showed significantly higher mean health care payments for individuals with a diagnosis of hearing loss during follow-up compared with patients without a diagnosis of hearing loss (Table 2). Patients with a diagnosis of hearing loss who received hearing services (36 323 of 280 882 patients [12.9%]) had slightly lower (by $368) overall mean costs ($13 797; 95% CI, $13 530-$14 069) than did patients who did not receive hearing services ($14 165; 95% CI, $14 091-$14 239) when we adjusted for the cost of hearing services; however, payments remained significantly higher (by $3168) than those for patients without hearing loss ($10 629; 95% CI, $10 576-$10 681).
Older middle-aged adults (aged 55-64 years) in our study with a diagnosis of hearing loss had substantially higher health care costs than a matched comparison group of patients without such a diagnosis. Our results mirror the finding by Genther et al1 that patients with hearing loss documented by audiometry had a higher risk of hospital admission than did patients without hearing loss, indicating that hearing loss may place patients at risk for increased health care use and costs. Our study is limited by the lack of audiometry confirmation of hearing loss and our inability to differentiate between successful hearing loss interventions and failed interventions. Residual confounding may remain owing to unmeasured variables. However, we observed 33.3% higher payments during a 1.5-year time period for a relatively young group of insured patients with hearing loss (mean, $14 165) vs patients without hearing loss (mean, $10 629). This finding indicates that negative health-related effects of hearing loss, a condition that many consider simply an unavoidable result of aging, may manifest earlier than is generally recognized and may affect use of health care across the continuum of care. Studies are needed to identify the underlying factors that lead to the observed cost differences, as well as to ascertain the extent to which early and successful use of hearing aids and other hearing loss interventions modify cost differences. Nevertheless, our study suggests that hearing loss is costly, even in middle-aged individuals, and is present in large numbers of adults for whom early, successful intervention may prevent future hearing-related disabilities and decreased quality of life.
Corresponding Author: Annie N. Simpson, PhD, Department of Healthcare Leadership and Management, Medical University of South Carolina, 151-B Rutledge Ave, Mail Stop Code 962, Charleston, SC 29425 (email@example.com).
Published Online: April 7, 2016. doi:10.1001/jamaoto.2016.0188.
Author Contributions: Dr A. N. Simpson had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: All authors.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: A. N. Simpson, K. N. Simpson.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: A. N. Simpson, K. N. Simpson.
Obtained funding: A. N. Simpson, Dubno.
Administrative, technical, or material support: A. N. Simpson, Dubno.
Study supervision: A. N. Simpson, Dubno.
Conflict of Interest Disclosures: None reported.
Funding/Support: This work was supported by grant R21 DC014031-01 from The National Institutes of Health/National Institute on Deafness and Other Communication Disorders and by the South Carolina Clinical and Translational Research Institute, with an academic home at the Medical University of South Carolina, through grant UL1 RR029882 from the National Institutes of Health. This investigation was conducted in a facility constructed with support from National Institutes of Health Research Facilities Improvement Program grant C06 RR14516.
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Create a personal account or sign in to: